PROGNOSTIC VALUE OF KI-67 AND VIMENTIN MARKERS IN PATIENTS WITH METASTATIC KIDNEY CANCER
- Authors: Gorelov A.I1, Narimanyan Z.N2, Gorelov D.S3
-
Affiliations:
- FSBEI HPE "Saint Petersburg State University"
- SBHCI "St. Petersburg Clinical Research Center for Specialized Types of Care (Oncological)"
- SPb SHCI "Pokrovsky City Hospital"
- Issue: No 3 (2014)
- Pages: 54-58
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/280197
- ID: 280197
Cite item
Open Access
Access granted
Abstract
The study was aimed to determine the role of ki- 67 and vimentin markers in choosing the tactics of surgical treatment of patients with metastatic kidney cancer. The analysis of the results of treatment of 71 patients with metastatic renal cell carcinoma was performed. The first group included 16 (22.5%) patients, who underwent complete removal of distant metastases after nephrectomy. The second group consisted of 55 (77.5 %) patients who underwent cytoreductive nephrectomy only. Immunohistochemical analyses of tissues removed were performed in all patients for the evaluation of ki-67 and vimentin expression levels. When comparing the outcomes of patients after complete removal of metastases depending on the vimentin and ki-67 expression levels (<10% and > 10%), a significant increase in the cumulative survival in the case of absence of vimentin and ki-67 expression of <10 % (log - rank test, P=0.0001) was revealed. The same pattern was noted in the group of patients who underwent nephrectomy only. In the absence of expression of vimentin and ki-67 <10%, survival rate in patients who underwent metastasectomy after nephrectomy was significantly higher compared with patients who underwent nephrectomy only (P=0.001). In the case of positive expression of vimentin and ki-67 > 10%, differences in survival rate in these groups were not observed (P>0.082). Thus, an association between the vimentin and ki-67 expression levels and the degree of spread of metastatic renal cell carcinoma was identified: the high level of expression of these markers precludes the increase of life expectancy of patients after removal of all metastases.
Keywords
Full Text
About the authors
A. I Gorelov
FSBEI HPE "Saint Petersburg State University"
Email: gorelov_a_i@maiI.ru
MD, Prof., Had of the Course of Urology at the Department of Hospital Surgery of Medical Faculty
Z. N Narimanyan
SBHCI "St. Petersburg Clinical Research Center for Specialized Types of Care (Oncological)"
D. S Gorelov
SPb SHCI "Pokrovsky City Hospital"
References
- Аляев Ю.Г. Современные технологии в диагностике и лечении рака почки. Онкоурология. 2005;2:3-8.
- Злокачественные новообразования в России в 2009 г. (заболеваемость и смертность) / Под ред. В.И Чиссова, В.В. Старинского, Г.В. Петровой. М. ФГУ «МНИОИ им. П.А. Герцена Минздравсоцразвития России». 2011. 260 с.
- Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 2008;34:193-205.
- Athar U., Gentile T. C. Treatment options for metastatic renal cell carcinoma: a review // Can. J. Urol. 2008;15:3954-3966.
- Матвеев В.Б., Волкова М.И. Лечение местнораспространенного и диссеминированного рака почки. Вместе против рака. 2006;1:35-39.
- Amato R.J. Chemotherapy for renal cell carcinoma. Semin. Oncol. 2000;27:177-186.
- Tomita Y., Imai T., Tanikawa T., Mizusawa T., Kanai T., Takahashi K. Treatment of bilateral renal cell cancer and multiple lung metastasis: nephron-sparing surgery and resection of lung tumors after interleukin-2 therapy. Eur. Urol. 1998; 33(2):238-240.
- Friedel G., Hurtgen M., Penzenstadler M., Kyriss T., Toomes H. Resection of pulmonary metastases from renal cell carcinoma. Anticancer. Res. 1999;19:1593-1596.
- Fottner A., Szalantzy M., Wirthmann L., Stahler M., Baur-Melnyk A., Jansson V., Durr H.R. Bone metastases from renal cell carcinoma: Patient survival after surgical treatment. BMC Musculoskelet. Disord. 2010;11(1):145.
- Dudderidge T.J., Stoeber K., Loddo M. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin. Cancer Res. 2005;11:2510-2517.
- Moch H., Schraml P., Bubendorf L., Mirlacher M., Kononen J., Gasser T., Mihatsch M.J., Kallioniemi O.P., Sauter G. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 1999;154:981-986.
- Visapää H., Bui M., Huang Y., Seligson D., Tsai H., Pantuck A., Figlin R., Rao J.Y., Belldegrun A., Horvath S., Palotie A. Correlation of ki-67 and gelsolin expression to clinical outcome in renal cell carcinoma. Urology. 2003;61(4):845-850.
- Kankuri M., Söderström K., Pelliniemi T.T., Vahlberg T., Pyrhönen S., Salminen E. The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Research. 2006; 26:3825-3834.
- Kim H.L., Seligson D., Liu X. Molecular staging using protein expression profiling in metastatic clear cell renal carcinoma. J. Urol. 2005;173:1496-1501.
- Kim H.L., Seligson D., Liu X. Using protein expression to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 2004;10:5464-5471.
Supplementary files
